BDBM359130 US10220048, Compound AA40::US10952992, No. AA40::US11413242, Compound AA40::US11666558, Example AA40::US12064420, Compound AA40::US20240299367, No. AA40

SMILES CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(O)(=O)=O)cc1)c1nc(cs1)C(C)(C)C

InChI Key InChIKey=RGULHINSXZCWCM-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 359130   

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
EyePoint Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM359130(US10220048, Compound AA40 | US10952992, No. AA40 |...)
Affinity DataIC50: 0.300nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
EyePoint Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM359130(US10220048, Compound AA40 | US10952992, No. AA40 |...)
Affinity DataIC50: 0.300nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
EyePoint Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM359130(US10220048, Compound AA40 | US10952992, No. AA40 |...)
Affinity DataIC50: 0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
EyePoint Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM359130(US10220048, Compound AA40 | US10952992, No. AA40 |...)
Affinity DataIC50: 0.300nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
EyePoint Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM359130(US10220048, Compound AA40 | US10952992, No. AA40 |...)
Affinity DataIC50: 0.300nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
EyePoint Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM359130(US10220048, Compound AA40 | US10952992, No. AA40 |...)
Affinity DataIC50: 0.300nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent